Harrow (HROW) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Phibro Animal Health (PAHC) has outperformed Harrow (HROW) over the past year, gaining 0.3% versus a loss of 23.2%. Over five years, HROW leads with a +208.6% price change compared with +73.0% for PAHC. Phibro Animal Health is the larger company by market cap ($1.52 billion vs $1.14 billion), about 1.3 times the size.
On valuation, Phibro Animal Health trades at a lower forward P/E (9.7x vs 11.0x for Harrow). Phibro Animal Health pays a dividend yielding 1.28%, while Harrow does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | PAHC |
|---|---|---|
| Share price | $30.52 | $37.40 |
| Market cap | $1.14B | $1.52B |
| 1-day change | -0.33% | -0.85% |
| YTD return | -37.71% | +0.96% |
| 1-year return | -23.20% | +0.27% |
| 5-year return | +208.59% | +73.03% |
| P/E ratio (TTM) | — | 15.39 |
| Forward P/E | 11.01 | 9.73 |
| EPS (TTM) | $-0.99 | $2.43 |
| Dividend yield | 0.00% | 1.28% |
| Annual dividend | $0.00 | $0.48 |
| 52-week high | $54.85 | $60.08 |
| 52-week low | $28.54 | $28.25 |
| Distance from 52-week high | -44.36% | -37.75% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +112.98% | +17.65% |
| Average volume | 555.55K | 236.19K |
| Shares outstanding | 37.49M | 21.11M |
| Employees | 373 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PAHC has outperformed HROW by 23.5 percentage points over the past year.
- Phibro Animal Health offers a meaningfully higher dividend yield (1.28% vs 0.00%).
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
HROW vs PAHC FAQ
Which is bigger, Harrow or Phibro Animal Health?
Phibro Animal Health (PAHC) is larger, with a market capitalization of $1.52B compared with $1.14B for Harrow (HROW).
Which stock has performed better over the past year, HROW or PAHC?
PAHC returned +0.27% over the past 12 months, compared with -23.20% for HROW (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Harrow or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.28%, while Harrow does not currently pay a regular dividend.
Are Harrow and Phibro Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.